News for Keros Therapeutics, Inc. (KROS)

LEXINGTON, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (”œKeros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused

Significant Reduction in Keros Therapeutics Holdings On December 31, 2024, ALKEON CAPITAL MANAGEMENT LLC (Trades, Portfolio) executed a notable reduction in its

On December 31, 2024, Darwin Global Management, Ltd. (Trades, Portfolio) executed a significant transaction involving Insmed Inc., a global biopharmaceutical co

On January 31, 2025, FMR LLC (Trades, Portfolio) executed a significant transaction involving Keros Therapeutics Inc. (NASDAQ: KROS), reducing its holdings by 4

KROS stock crashes 81% in three months after dosing with cibotercept was halted in a phase II lung disease study due to adverse pericardial effusion events.

Keros Therapeutics (KROS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Keros Therapeutics (KROS) stock rises as a licensing deal with Takeda (TAK) begins. However, Cantor Fitzgerald downgrades, citing a trial setback. Read more here.

Keros stock climbs on Takeda deal effectiveness

Keros Therapeutics seals $200M deal with Takeda

LEXINGTON, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (”œKeros” or the ”œCompany”) ( KROS), a clinical-stage biopharmaceutical co

The heavy selling pressure might have exhausted for Keros Therapeutics (KROS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Keros Therapeutics (KROS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

U.S. stocks traded higher toward the end of trading, with the S&P 500 gaining over 100 points on Wednesday. The Dow traded up 1.69% to 43,237.93 while the NASD...

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 2% on Wednesday. The Dow traded up 1.68% to 43,232.26 while the N...

Florida- based Safe & Green Holdings Corp. (SGBX) is up over 155 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.53%

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 200 points on Thursday. The Dow traded down 0.46% to 43,947.18 whil...

U.S. stocks traded lower midway through trading, with the Dow Jones index falling by 0.2% on Thursday. The Dow traded down 0.18% to 44,067.70 while the NASDAQ ...

U.S. stocks traded mostly lower this morning, with the Nasdaq Composite falling more than 50 points on Thursday. Following the market opening Thursday, the Dow...